Gemifloxacin for the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis and Community-Acquired Pneumonia

P and T

Volumn 28, Issue 12, 2003, Pages 769-770+777

  Chagan, Larisa ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; CALCIUM CARBONATE; CEFETIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FERROUS SULFATE; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUCRALFATE; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN;

ADVERSE DRUG REACTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CHRONIC BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG USE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; PENICILLIN RESISTANCE; RASH; RESPIRATORY DISTRESS; REVIEW; UNITED STATES; URTICARIA; VOMITING;

EID: 1242294577     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Gemifloxacin (Factive®, GeneSoft) prescribing information. Available at www.fda.gov/cder/foi/label/2003/21158_factive_lbl.pdf. Accessed November 3, 2003.
2. Niederman MS, McCombs JS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999;21:576-591.
3. Bilas A. Lower respiratory tract infections. Primary Care 1990;17:811-824.
4. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;113(Suppl);199S-203S.
5. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995;99(Suppl 6B):3S-7S.
6. Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-993.
7. Doern GV, Bueffemann A, Holley HP Jr, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208-1213.
8. Cunha BA, Shea KW. Emergence of antimicrobial resistance in community-acquired pulmonary pathogens. Semin Respir Infect 1998;13(1):43-53.
9. Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis 2000;31:347-382.
10. Marrie TJ. Community-acquired pneumonia: Epidemiology, etiology, treatment. Infect Dis Clin North Am 1998;12:723-740.
11. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635-692.
12. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Molec Biol Rev 1997;61:377-392.
13. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 2002;8:79-84.
14. Zhanel GG, Roberts D, Waltky A, et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2002;49:807-812.
15. Allen A, Bygate E, Oliver S, et al. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob Agents Chemother 2000;44:1604-1608.
16. Allen A, Bygate E, Vousden M, et al. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob Agents Chemother 2001;45:540-545.
17. Davy M, Allen A, Bird N, et al. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Chemotherapy 1999; 45:478-484.
18. Vousden M, Allen A, Lewis A, Ehren N. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers. Chemotherapy 1999;45:485-490.
19. Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy 1999; 45:491-495.
20. Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy 1999;45:504-511.
21. Pletz MW, Petzold P, Allen A, et al. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003;47:2158-2160.
22. Allen A, Vousden M, Lewis A. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Chemotherapy 1999;45:496-503.
23. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 2002;8:79-84.
24. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081.
25. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
26. Preston SL, Drusano GI, Berman AL, et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998;279:125-129.
27. Woodnutt G. Pharmacodynamics to combat resistance. J Antimicrob Chemother 2000 46:25-31.
28. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001;47:129-140.
29. Wilson R, Schentag JJ, Ball P, Mandell L: The 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-652.
30. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: Results from the GLOBE study. Am J Health Syst Pharm 2002;59:1357-1365.
31. File T, Schlemmer B, Garau J, et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis: The 070 Clinical Study Group. J Chemother 2000;12:314-325.
32. Ball P, Wilson R, Mandell L, et al: The 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: A randomized, double-blind comparison with trovafloxacin. J Chemother 2001;13:288-298.
33. Wilson R, Langan C, Ball P, et al: The Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with IV ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003;97:242-249.
34. Ball P, File TM, Twynholm M, Henkel T. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001;18:19-27.
35. Lode H, File TM Jr, Mandell L, et al: The 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002;24:1915-1936.
36. File TM Jr, Schlemmer B, Garau J, et al: The 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001;48:67-74.